News

Published on 1 Dec 2022 on Zacks via Yahoo Finance

Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet


Article preview image

Shares of Annexon, Inc. (ANNX) have gained 17.5% over the past four weeks to close the last trading session at $5.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.57 indicates a potential upside of 241.4%.

The average comprises seven short-term price targets ranging from a low of $7 to a high of $30, with a standard deviation of $7.79. While the lowest estimate indicates an increase of 28.7% from the current price level, the most optimistic estimate points to a 451.5% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.

NASDAQ.ANNX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc

Overview of Steven Cohen (Trades, Portfolio)'s Investment in Annexon Inc Warning! GuruFocus has d...

GuruFocus.com via Yahoo Finance 13 Feb 2024

Recent uptick might appease Annexon, Inc. (NASDAQ:ANNX) institutional owners after losing 18% over...

Key Insights Given the large stake in the stock by institutions, Annexon's stock price might be v...

Simply Wall St. via Yahoo Finance 10 Feb 2024

Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the gro...

Zacks via Yahoo Finance 17 Jan 2024

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

Annexon, Inc. ANNX, a clinical-stage company, is focused on developing novel therapies to treat p...

Zacks via Yahoo Finance 14 Jan 2024

Muneer Satter Bought 5.9% More Shares In Annexon

Those following along with Annexon, Inc. (NASDAQ:ANNX) will no doubt be intrigued by the recent p...

Simply Wall St. via Yahoo Finance 31 Dec 2023

Annexon: ANX007 Advances Forward With Stellar Endpoint (NASDAQ:ANNX)

Annexon, Inc. has a promising complement inhibitor ANX007 treatment of patients with Geographic...

Seeking Alpha 23 Dec 2023

Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's...

Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's...

Investing.com 21 Dec 2023

Nasdaq Gains 100 Points; CarMax Earnings Top Views - Clene (NASDAQ:CLNN), Annexon (NASDAQ:ANNX)

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 1...

Benzinga 21 Dec 2023

Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)

Annexon, Inc. (ANNX) has been on a downward spiral lately with significant selling pressure. Afte...

Zacks via Yahoo Finance 8 Sep 2023

Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study

Annexon Inc (NASDAQ: ANNX) announced topline results from its ARCHER Phase 2 trial of ANX007 in p...

Benzinga via Yahoo Finance 28 May 2023